Read our latest eMag
Read Now

Osborne Clarke advises NeRRe Therapeutics on its £20 million Series B2 financing round

By Karolina Lasinska
13 July 2021
Share

Reading-based lawyers from law firm Osborne Clarke have advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by a new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.

The Osborne Clarke team was led by corporate and venture capital partner Justin Starling (pictured) and associate director Elizabeth Yell.

NeRRe Therapeutics is a clinical stage company developing orvepitant, its wholly owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders.

The proceeds from the financing round will primarily be used to fund the Phase 2 clinical development of orvepitant as a treatment for chronic cough associated with IPF.